共 10 条
[1]
Thomas AA(2009)Surgical resection of renal cell carcinoma after targeted therapy J. Urol. 182 881-886
[2]
Flanigan RC(2004)Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J. Urol. 171 1071-1076
[3]
Motzer RJ(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 356 115-124
[4]
Hudes G(2007)Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N. Engl. J. Med. 356 2271-2281
[5]
Escudier B(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N. Engl. J. Med. 356 125-134
[6]
Amin C(2008)Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy Urology 72 864-868
[7]
Bex A(2009)Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery World J. Urol. 27 533-539
[8]
Karakiewicz PI(2008)Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi Eur. Urol. 53 845-848
[9]
Shuch B(2008)Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm BJU Int. 102 692-696
[10]
Margulis V(2008)Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J. Urol. 180 94-98